Health & Environmental Research Online (HERO)


Print Feedback Export to File
6606490 
Legal Material 
Patent 
Diphenylethylene compounds 
Nag, B; Medicherla, S; Dey, D 
2003 
Calyx Therapeutics, Inc. 
4 
BCI:BCI200300485693 
Novel diphenylethylene and styrenes are provided which are administered orally to decrease blood glucose levels in rats. The glucose tolerance in insulin resistant rats is also shown, as well as lowering of triglyceride levels in serum insulin resistant, hyperinsulinemic and hypertriglycedemic rats. The compounds are orally effective anti-diabetic agents that potentially may reduce abnormality of glucose and lipid metabolism in diabetes.